Membrane cholesterol as a mediator of the neuroprotective effects of estrogens

Neuroscience

Volumn 191, Issue , 2011, Pages 107-117

  Peri, A ^a   Benvenuti, S ^a   Luciani, P ^a   Deledda, C ^a   Cellai, I ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Alzheimer's disease; Cholesterol; Estrogens; IGF 1; Neurodegeneration; Seladin 1

Indexed keywords

3 BETA HYDROXYSTEROL DELTA 24 REDUCTASE; AMYLOID BETA PROTEIN; CHOLESTEROL; DESMOSTEROL; ESTRADIOL; ESTROGEN; RALOXIFENE; SOMATOMEDIN C; STEROID REDUCTASE; TAMOXIFEN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CATALYSIS; CHOLESTEROL SYNTHESIS; CORRELATIONAL STUDY; ENZYME ACTIVITY; FETUS CELL; GENE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; NERVE CELL NECROSIS; NEUROBLASTOMA CELL; NEUROEPITHELIUM; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SELADIN 1 GENE;

ALZHEIMER DISEASE; ANIMALS; APOPTOSIS; BRAIN; CELL MEMBRANE; CHOLESTEROL; ESTROGENS; HUMANS; MODELS, BIOLOGICAL; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS;

EID: 80052269266     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.03.011     Document Type: Review

References (83)

1. Abad-Rodriguez J., Ledesma M.D., Craessaerts K., Perga S., Medina M., Delacourte A., Dingwall C., De Strooper B., Dotti C. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 2004, 167:953-960.
2. Arbogast L.A. Estrogen genomic and membrane actions at an intersection. Trends Endocrinol Metab 2008, 19:1-2.
3. Arispe N., Doh M. Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AbetaP (1-40) and (1-42) peptides. FASEB J 2002, 16:1526-1536.
4. Barni T., Maggi M., Fantoni G., Granchi S., Mancina R., Gulisano M., Marra F., Macorsini E., Luconi M., Rotella C., Serio M., Balboni G.C., Vannelli G.B. Sex steroids and odorants modulate gonadotropin-releasing hormone secretion in primary cultures of human olfactory cells. J Clin Endocrinol Metab 1999, 84:4266-4273.
5. Battista M.C., Roberge C., Otis M., Gallo-Payet N. Seladin-1 expression in rat adrenal gland: effect of adrenocorticotropic hormone treatment. J Endocrinol 2007, 192:53-66.
6. Baulieu E.E. Neurosteroids: a novel function of the brain. Psychoneuroendocrinology 1998, 23:963-987.
7. Behl C. Estrogen can protect neurons: modes of action. J Steroid Biochem Mol Biol 2003, 83:195-197.
8. Benarroch E.E. Neurosteroids: endogenous modulators of neuronal excitability and plasticity. Neurology 2007, 68:945-947.
9. Benvenuti S., Luciani P., Vannelli G.B., Gelmini S., Franceschi E., Serio M., Peri A. Estrogen and SERMs exert neuroprotective effects and stimulate the expression of seladin-1, a recently discovered anti-apoptotic gene, in human neuroblast long-term cell cultures. J Clin Endocrinol Metab 2005, 90:1775-1782.
10. Biancolella M., Valentini A., Minella D., Vecchione L., D'Amico F., Chillemi G., Gravina P., Bueno S., Prosperini G., Desideri A., Federici G., Bernardini S., Novelli G. Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest New Drugs 2007, 25:491-497.
11. Björkhem I., Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004, 24:806-815.
12. Bonaccorsi L., Luciani P., Nesi G., Mannucci E., Deledda C., Dichiara F., Paglierani M., Rosati F., Masieri L., Serni S., Carini M., Proietti-Pannunzi L., Monti S., Forti G., Danza G., Serio M., Peri A. Androgen receptor regulation of the seladin-1/DHCR24 gene: altered expression in prostate cancer. Lab Invest 2008, 88:1049-1056.
13. Carbonaro V., Caraci F., Giuffrida M.L., Merlo S., Canonico P.L., Drago F., Copani A., Sortino M.A. Enhanced expression of ERalpha in astrocytes modifies the response of cortical neurons to beta-amyloid toxicity. Neurobiol Dis 2003, 33:415-421.
14. Cecchi C., Rosati F., Pensalfini A., Formigli L., Nosi D., Liguri G., Dichiara F., Morello M., Danza G., Pieraccini G., Peri A., Serio M., Stefani M. Seladin-1/DHCR24 protects neuroblastoma cells against Abeta toxicity by increasing membrane cholesterol content. J Cell Mol Med 2008, 12:1990-2002.
15. Crameri A., Biondi E., Kuehnle K., Lütjohann D., Thelen K.M., Perga S., Dotti C.G., Nitsch R.M., Ledesma M.D., Mohajeri M.H. The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo. EMBO J 2006, 25:432-443.
16. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E. Akt phosphorylation of BAD couples survival signals to cell-intrinsic machinery. Cell 1997, 91:231-241.
17. Del Peso L., González-García M., Page C., Herrera R., Nuñez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997, 278:687-689.
18. Dhandapani K.M., Brann D.W. Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol Reprod 2002, 67:1379-1385.
19. Di Stasi D., Vallacchi V., Campi V., Ranzani T., Daniotti M., Chiodini E., Fiorentini S., Greeve I., Prinetti A., Rivoltini L., Pierotti M.A., Rodolfo M. DHCR24 gene expression is upregulated in melanoma metastases and associated to resistance to oxidative stress-induced apoptosis. Int J Cancer 2005, 115:224-230.
20. Dong Y., Zhang H., Gao A.C., Marshall J.R., Ip C. DHCR24-knockout embryonic fibroblasts are susceptible to serum withdrawal-induced apoptosis because of dysfunction of caveolae and insulin-Akt-Bad signaling. Mol Cancer Ther 2005, 4:1047-1055.
21. Du B., Ohmichi M., Takahashi K., Kawagoe J., Ohshima C., Igarashi H., Mori-Abe A., Saitoh M., Ohta T., Ohishi A., Doshida M., Tezuka N., Takahashi T., Kurachi H. Both estrogen and raloxifene protect against beta-amyloid-induced neurotoxicity in estrogen receptor alpha-transfected PC12 cells by activation of telomerase activity via Akt cascade. J Endocrinol 2004, 183:605-615.
22. Fester L., Zhou L., Bütow A., Huber C., von Lossow R., Prabge-Kiel J., Jarry H., Rune G.M. Cholesterol-promoted synaptogenesis requires the conversion of cholesterol to estradiol in the hippocampus. Hippocampus 2009, 19:692-705.
23. Fillit H.M. The role of hormone replacement therapy in the prevention of Alzheimer's disease. Arch Intern Med 2002, 162:1934-1942.
24. FitzPatrick D.R., Keeling J.W., Evans M.J., Kan A.E., Bell J.E., Porteous M.E., Mills K., Winter R.M., Clayton P.T. Clinical phenotype of desmosterolosis. Am J Med Genet 1998, 75:145-152.
25. Font de Mora J., Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000, 20:5041-5047.
26. Frago L.M., Pañeda C., Dickson S.L., Hewson A.K., Argente J., Chowen J.A. Growth hormone (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-I expression and activate intracellular signaling pathways involved in neuroprotection. Endocrinology 2002, 143:4113-4122.
27. Fuller P.J., Alexiadis M., Jobling T., McNeilage J. Seladin-1/DHCR24 expression in normal ovary, ovarian epithelial and granulosa tumours. Clin Endocrinol (Oxf) 2005, 63:111-115.
28. Garcia-Segura L.M., Arévalo M.A., Azcoitia I. Interactions of estradiol and insulin-like growth factor-I signalling in the nervous system: new advances. Prog Brain Res 2010, 181:251-272.
29. Giannini S., Benvenuti S., Luciani P., Manuelli C., Cellai I., Deledda C., Pezzatini A., Vannelli G.B., Maneschi E., Rotella C.M., Serio M., Peri A. Intermittent high glucose concentrations reduce neuronal precursor survival by altering the IGF system: the involvement of the neuroprotective factor seladin-1. J Endocrinol 2008, 198:523-532.
30. Greeve I., Hermans-Borgmeyer I., Brellinger C., Kasper D., Gomez-Isla T., Behl C., Levkau B., Nitsch R.M. The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. J Neurosci 2000, 20:7345-7352.
31. Hawkins M.B., Thornton J.W., Crews D., Skipper J.K., Dotte A., Thomas P. Identification of a third distinct estrogen receptor and reclassification of estrogen receptors in teleosts. Proc Natl Acad Sci U S A 2000, 97:10751-10756.
32. Henderson V.W. Alzheimer's disease and other neurological disorders. Climacteric 2007, 10(Suppl 2):92-96.
33. Hendriksen P.J., Dits N.F., Kokame K., Veldhoven A., van Weerden W.M., Bangma C.H., Trapman J., Jenster G. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 2006, 66:5012-5020.
34. Herman G.E. Disorders of cholesterol biosynthesis: prototypic metabolic malformation syndromes. Hum Mol Genet 2003, 12(Spec No 1):R75-R88.
35. Hu X.Y., Qin S., Lu Y.P., Ravid R., Swaab D.F., Zhou J.N. Decreased estrogen receptor-α expression in hippocampal neurons in relation to hyperphosphorylated tau in Alzheimer patients. Acta Neuropathol 2003, 106:213-220.
36. Iivonen S., Hiltunen M., Alafuzoff I., Mannermaa A., Kerokoski P., Puoliväli J., Salminen A., Helisalmi S., Soininen H. Seladin-1 transcription is linked to neuronal degeneration in Alzheimer's disease. Neuroscience 2002, 113:301-310.
37. Kaether C., Haass C. A lipid boundary separates APP and secretases and limits amyloid beta-peptide generation. J Cell Biol 2004, 167:809-812.
38. Kuehnle K., Crameri A., Kälin R.E., Luciani P., Benvenuti S., Peri A., Ratti F., Rodolfo M., Kulic L., Heppner F.L., Nitsch R.M., Mohajeri M.H. Prosurvival effect of DHCR24/Seladin-1 in acute and chronic responses to oxidative stress. Mol Cell Biol 2008, 28:539-550.
39. Lavaque E., Sierra A., Azcoitia I., Garcia-Segura L.M. Steroidogenic acute regulatory protein in the brain. Neuroscience 2006, 138:741-747.
40. Lu X., Kambe F., Cao X., Kozaki Y., Kaji T., Ishii T., Seo H. DHCR24 is a hydrogen peroxide scavenger, protecting cells from oxidative-stress-induced apoptosis. Endocrinology 2008, 149:3267-3273.
41. Luciani P., Deledda C., Rosati F., Benvenuti S., Cellai I., Dichiara F., Morello M., Vannelli G.B., Danza G., Serio M., Peri A. Seladin-1 is a fundamental mediator of the neuroprotective effects of estrogen in human neuroblast long-term cell cultures. Endocrinology 2008, 149:4256-4266.
42. Luciani P., Ferruzzi P., Arnaldi G., Crescioli C., Benvenuti S., Nesi G., Valeri A., Greeve I., Serio M., Mannelli M., Peri A. Expression of the novel adrenocorticotropic-responsive gene seladin-1/DHCR24 in the normal adrenal cortex and in adrenocortical adenomas and carcinomas. J Clin Endocrinol Metab 2004, 89:1332-1339.
43. Luciani P., Gelmini S., Ferrante E., Lania A., Benvenuti S., Baglioni S., Mantovani G., Cellai I., Ammannati F., Spada A., Serio M., Peri A. Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2005, 90:6156-6161.
44. Ma Z.Q., Santagati S., Patrone C., Pollio G., Vegeto E., Maggi A. Insulin-like growth factors activate estrogen receptor to control the growth and differentiation of the human neuroblastoma cell line SK-ER3. Mol Endocrinol 1994, 8:910-918.
45. MacLusky N.J. Estrogen and Alzheimer's disease: the apolipoprotein connection. Endocrinology 2004, 145:3062-3064.
46. Maggi A., Ciana P., Belcredito S., Vegeto E. Estrogens in the nervous system: mechanisms and nonreproductive functions. Annu Rev Physiol 2004, 66:291-313.
47. Marin R., Guerra B., Hernández-Jiménez J.G., Kang X.L., Fraser J.D., Lopez F.J., Alonso R. Estradiol prevents amyloid-beta peptide-induced cell death in a cholinergic cell line via modulation of a classical estrogen receptor. Neuroscience 2009, 12:917-926.
48. Matthews C.C., Feldman E.L. Insulin-like growth factor I rescues SH-SY5Y human neuroblastoma cells from hyperosmotic induced programmed cell death. J Cell Physiol 1996, 166:323-331.
49. Mendez P., Azcoitia I., Garcia-Segura L.M. Interdependence of oestrogen and insulin-like growth factor-I in the brain: potential for analyzing neuroprotective mechanisms. J Endocrinol 2005, 185:11-17.
50. Mendez P., Garcia-Segura L.M. Phosphatidylinositol 3 kinase (PI3K) and glycogen synthase kinase 3 (GSK3) regulate estrogen receptor-mediated transcription in neuronal cells. Endocrinology 2006, 147:3027-3039.
51. Mirza R., Hayasaka S., Kambe F., Maki K., Kaji T., Murata Y., Seo H. Increased expression of aquaporin-3 in the epidermis of DHCR24 knockout mice. Br J Dermatol 2008, 158:679-684.
52. Mirza R., Hayasaka S., Takagishi Y., Kambe F., Ohmori S., Maki K., Yamamoto M., Murakami K., Kaji T., Zadworny D., Murata Y., Seo H. DHCR24 gene knockout mice demonstrate lethal dermopathy with differentiation and maturation defects in the epidermis. J Invest Dermatol 2006, 126:638-647.
53. Ning Y., Chen S., Li X., Ma Y., Zhao F., Yin L. Cholesterol, LDL, and 25-hydroxycholesterol regulate expression of the steroidogenic acute regulatory protein in microvascular endothelial cell line (bEnd3). Biochem Biophys Res Commun 2006, 342:1249-1256.
54. O'Neill K., Chen S., Brinton R.D. Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with aging and Alzheimer's disease. Exp Neurol 2004, 185:63-80.
55. O'Neill K., Chen S., Brinton R.D. Impact of the selective estrogen receptor modulator, tamoxifen, on neuronal outgrowth and survival following toxic insults associated with aging and Alzheimer's disease. Exp Neurol 2004, 188:268-278.
56. Paganini-Hill V.W., Henderson V.W. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994, 140:256-261.
57. Patisaul H.B. Phytoestrogen action in the adult and developing brain. J Neuroendocrinol 2005, 17:57-64.
58. Patrone C., Gianazza E., Santagati S., Agrati P., Maggi A. Divergent pathways regulate ligand-independent activation of ER alpha in SK-N-BE neuroblastoma and COS-1 renal carcinoma cells. Mol Endocrinol 1998, 12:835-841.
59. Rapp S.R., Espeland M.A., Shumaker S.A., Henderson V.W., Brunner R.L., Manson J.E., Gass M.L., Stefanick M.L., Lane D.S., Hays J., Johnson K.C., Coker L.H., Dailey M., Bowen D. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003, 289:2663-2672. WHIMS Investigators.
60. Reiss A.B., Siller K.A., Rahman M.M., Chan E.S., Ghiso J., De Leon M.J. Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer's disease. Neurobiol Aging 2004, 25:977-989.
61. Reyland M.E., Evans R.M., White E.K. Lipoproteins regulate expression of the steroidogenic acute regulatory protein (StAR) in mouse adrenocortical cells. J Biol Chem 2000, 275:36637-36644.
62. Russo V.C., Gluckman P.D., Feldman E.L., Werther G.A. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev 2005, 26:916-943.
63. Russo V.C., Kobayashi K., Najdovska S., Baker N.L., Werther G.A. Neuronal protection from glucose deprivation via modulation of glucose transport and inhibition of apoptosis: a role for the insulin-like growth factor system. Brain Res 2004, 1009:40-53.
64. Sarkar D., Imai T., Kambe F., Shibata A., Ohmori S., Siddiq A., Hayasaka S., Funahashi H., Seo H. The human homolog of Diminuto/Dwarf1 gene (hDiminuto): a novel ACTH-responsive gene overexpressed in benign cortisol-producing adrenocortical adenomas. J Clin Endocrinol Metab 2001, 86:5130-5137.
65. Schumacher M., Guennoun R., Ghoumari A., Massaad C., Robert F., El-Etr M., Akwa Y., Rajkowski K., Baulieu E.E. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. Endocr Rev 2007, 28:387-439.
66. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001, 81:741-776.
67. Setchell K.D. Soy isoflavones-benefits and risks from nature's selective estrogen receptor modulators (SERMs). J Am Coll Nutr 2001, 20:354S-362S.
68. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., Ockene J.K., Hendrix S.L., Jones B.N., Assaf A.R., Jackson R.D., Kotchen J.M., Wassertheil-Smoller S., Wactawski-Wende J. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in post-menopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003, 289:2651-2662. WHIMS Investigators.
69. Toran-Allerand C.D. Minireview: a plethora of estrogen receptors in the brain: where will it end?. Endocrinology 2004, 145:1069-1074.
70. Turgeon J.L., Carr M.C., Maki P.M., Mendelsohn M.E., Wise P. Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: insights from basic science and clinical studies. Endocr Rev 2006, 27:576-605.
71. Vannelli G.B., Ensoli F., Zonefrati R., Kubota Y., Arcangeli A., Becchetti A., Camici G., Barni T., Thiele C.J., Balboni G.C. Neuroblast long-term cell cultures from human fetal olfactory epithelium respond to odors. J Neurosci 1995, 15:4282-4294.
72. Vasudeven N., Pfaff D.W. Membrane-initiated actions of estrogens in neuroendocrinology: emerging principles. Endocr Rev 2008, 28:1-19.
73. Veiga S., Melcangi R.C., Doncarlos L.L., Garcia-Segura L.M., Azcoitia I. Sex hormones and brain aging. Exp Gerontol 2004, 39:1623-1631.
74. Wang L., Andersson S., Warner M., Gustafsson J.A. Morphological abnormalities in the brains of estrogen receptor beta knockout mice. Proc Natl Acad Sci U S A 2001, 98:2792-2796.
75. Waterham H.R., Koster J., Romeijn G.J., Hennekam R.C., Vreken P., Andersson H.C., FitzPatrick D.R., Kelley R.I., Wanders R.J. Mutations in the 3beta-hydroxysterol Delta24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. Am J Hum Genet 2001, 69:685-694.
76. Wechsler A., Brafman A., Shafir M., Heverin M., Gottlieb H., Damari G., Gozlan-Kelner S., Spivak I., Moshkin O., Fridman E., Becker Y., Skaliter R., Einat P., Faerman A., Björkhem I., Feinstein E. Generation of viable cholesterol-free mice. Science 2003, 19:2079-2087.
77. Wu C., Miloslavskaya I., Demontis S., Maestro R., Galaktionov K. Regulation of cellular response to oncogenic and oxidative stress by Seladin-1. Nature 2002, 432:640-645.
78. Yaffe K., Krueger K., Cummings S.R., Blackwell T., Henderson V.W., Sarkar S., Ensrud K., Grady D. Effect of raloxifene on prevention of dementia and cognitive imparirment in older women: the Multiple Outcome of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 2005, 162:683-690.
79. Yanagisawa K. Cholesterol and pathological processes in Alzheimer's disease. J Neurosci Res 2002, 70:361-366.
80. Yao J.K., Wengenack T.M., Curran G.L., Poduslo J.F. Reduced membrane lipids in the cortex of Alzheimer's disease transgenic mice. Neurochem Res 2009, 34:102-108.
81. Zandi P.P., Carlson M.C., Plassman B.L., Welsh-Bohmer K.A., Mayer L.S., Steffens D.C., Breitner J.C. Cache County Memory Study Investigators, hormone replacement therapy and incidence of Alzheimer disease in older women. JAMA 2002, 288:2123-2129.
82. Znamensky V., Akama K.T., McEwen B.S., Milner T.A. Estrogen levels regulate the subcellular distribution of phosphorylated Akt in hippocampal CA1 dendrites. J Neurosci 2003, 23:2340-2347.
83. Zou C.G., Cao X.Z., Zhao Y.S., Gao S.Y., Li S.D., Liu X.Y., Zhang Y., Zhang K.Q. The molecular mechanism of endoplasmic reticulum stress-induced apoptosis in PC-12 neuronal cells: the protective effect of insulin-like growth factor I. Endocrinology 2009, 150:277-285.